Separate healthcare investments signaled continued scaling of research infrastructure and clinical access initiatives. In Houston, Bristol Myers Squibb selected the site for a $2.3 billion multi-modal manufacturing campus spanning small molecules, biologics and ADCs, while other reports pointed to efforts aimed at speeding first-in-human starts and expanding where trials are run.